Webdisclosure.com

Search

SANOFI-AVENTIS (EPA:SAN) Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months

Directive transparence : information réglementée

30/08/2021 07:00